{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:27:47Z","timestamp":1708043267370},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,15]]},"DOI":"10.7759\/cureus.54252","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T19:32:16Z","timestamp":1708025536000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Safety and Efficacy of Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation: A Systemic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ghazala S","family":"Virk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raheel","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa M","family":"Moazam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arhum","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faraz","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Zaheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahroz M","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedika","family":"Rajasekaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al.. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021, 42:373-498. 10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12766","article-title":"Rivaroxaban precision dosing strategy for real-world atrial fibrillation patients","volume":"13","author":"Konicki R","year":"2020","unstructured":"Konicki R, Weiner D, Herbert Patterson J, et al.. Rivaroxaban precision dosing strategy for real-world atrial fibrillation patients. Clin Transl Sci. 2020, 13:777-84. 10.1111\/cts.12766","journal-title":"Clin Transl Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej J","year":"2020","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020, 127:4-20. 10.1161\/CIRCRESAHA.120.316340","journal-title":"Circ Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-51. 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezw313","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"50","author":"Kirchhof P","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al.. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016, 50:e1-e88. 10.1093\/ejcts\/ezw313","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00230-9","article-title":"Primary stroke prevention worldwide: translating evidence into action","volume":"7","author":"Owolabi MO","year":"2022","unstructured":"Owolabi MO, Thrift AG, Mahal A, et al.. Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health. 2022, 7:e74-85. 10.1016\/S2468-2667(21)00230-9","journal-title":"Lancet Public Health"},{"key":"ref8","article-title":"Rivaroxaban","author":"Singh R","year":"2024","unstructured":"Singh R. Rivaroxaban. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-020-00434-w","article-title":"The pharmacology, efficacy, and safety of rivaroxaban in obese patient populations","volume":"21","author":"Ashton V","year":"2021","unstructured":"Ashton V, Mudarris L, Moore KT. The pharmacology, efficacy, and safety of rivaroxaban in obese patient populations. Am J Cardiovasc Drugs. 2021, 21:283-97. 10.1007\/s40256-020-00434-w","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03440100104016","article-title":"Minimizing the three stages of publication bias","volume":"263","author":"Chalmers TC","year":"1990","unstructured":"Chalmers TC, Frank CS, Reitman D. Minimizing the three stages of publication bias. JAMA. 1990, 263:1392. 10.1001\/jama.1990.03440100104016","journal-title":"JAMA"},{"key":"ref13","unstructured":"Critical Appraisal Skills Programme. CASP Systematic Review Checklist. (2018). Accessed. January 19, 2024: https:\/\/casp-uk.net\/checklists\/casp-systematic-review-checklist-fillable.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray WA","year":"2021","unstructured":"Ray WA, Chung CP, Stein CM, et al.. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021, 326:2395-404. 10.1001\/jama.2021.21222","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation : a multinational population-based cohort study","volume":"175","author":"Lau WC","year":"2022","unstructured":"Lau WC, Torre CO, Man KK, et al.. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation : a multinational population-based cohort study. Ann Intern Med. 2022, 175:1515-24. 10.7326\/M22-0511","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.025554","article-title":"Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin","volume":"51","author":"Alberts M","year":"2020","unstructured":"Alberts M, Chen YW, Lin JH, Kogan E, Twyman K, Milentijevic D. Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin. Stroke. 2020, 51:549-55. 10.1161\/STROKEAHA.119.025554","journal-title":"Stroke"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21884-y","article-title":"Effectiveness and safety of different rivaroxaban dosage regimens in patients with non-valvular atrial fibrillation: a nationwide, population-based cohort study","volume":"8","author":"Huang HY","year":"2018","unstructured":"Huang HY, Lin SY, Cheng SH, Wang CC. Effectiveness and safety of different rivaroxaban dosage regimens in patients with non-valvular atrial fibrillation: a nationwide, population-based cohort study. Sci Rep. 2018, 8:3451. 10.1038\/s41598-018-21884-y","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-022-02763-w","article-title":"Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation","volume":"55","author":"Jansson M","year":"2023","unstructured":"Jansson M, Sj\u00e4lander S, Sj\u00f6gren V, Bj\u00f6rck F, Renlund H, Norrving B, Sj\u00e4lander A. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation. J Thromb Thrombolysis. 2023, 55:415-25. 10.1007\/s11239-022-02763-w","journal-title":"J Thromb Thrombolysis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref20","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4. (2020). Accessed. March 1, 2022: https:\/\/training.cochrane.org\/system\/files\/uploads\/protected_file\/RevMan5.4_user_guide.pdf."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli AP","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, et al.. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022, 145:242-55. 10.1161\/CIRCULATIONAHA.121.056355","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es HP","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, de Barros E Silva PG, et al.. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020, 383:2117-26. 10.1056\/NEJMoa2029603","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2984","article-title":"Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial","volume":"77","author":"Perera KS","year":"2020","unstructured":"Perera KS, Ng KK, Nayar S, et al.. Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial. JAMA Neurol. 2020, 77:43-8. 10.1001\/jamaneurol.2019.2984","journal-title":"JAMA Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2021.02.004","article-title":"Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF","volume":"236","author":"Blumer V","year":"2021","unstructured":"Blumer V, Rivera M, Corbal\u00e1n R, et al.. Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. Am Heart J. 2021, 236:4-12. 10.1016\/j.ahj.2021.02.004","journal-title":"Am Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2021.02.021","article-title":"Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis","volume":"236","author":"Akao M","year":"2021","unstructured":"Akao M, Yasuda S, Kaikita K, et al.. Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. Am Heart J. 2021, 236:59-68. 10.1016\/j.ahj.2021.02.021","journal-title":"Am Heart J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz427","article-title":"A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial","volume":"40","author":"Mehra MR","year":"2019","unstructured":"Mehra MR, Vaduganathan M, Fu M, et al.. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J. 2019, 40:3593-602. 10.1093\/eurheartj\/ehz427","journal-title":"Eur Heart J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0617","article-title":"Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial","volume":"76","author":"Healey JS","year":"2019","unstructured":"Healey JS, Gladstone DJ, Swaminathan B, et al.. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol. 2019, 76:764-73. 10.1001\/jamaneurol.2019.0617","journal-title":"JAMA Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02077-9","article-title":"Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation","volume":"50","author":"Zhang L","year":"2020","unstructured":"Zhang L, Yan X, Fox KA, et al.. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2020, 50:20-9. 10.1007\/s11239-020-02077-9","journal-title":"J Thromb Thrombolysis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017728295","article-title":"Effect of renal function on dosing of non-vitamin k antagonist direct oral anticoagulants among patients with nonvalvular atrial fibrillation","volume":"52","author":"Shrestha S","year":"2018","unstructured":"Shrestha S, Baser O, Kwong WJ. Effect of renal function on dosing of non-vitamin k antagonist direct oral anticoagulants among patients with nonvalvular atrial fibrillation. Ann Pharmacother. 2018, 52:147-53. 10.1177\/1060028017728295","journal-title":"Ann Pharmacother"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12683","article-title":"Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study","volume":"283","author":"Staerk L","year":"2018","unstructured":"Staerk L, Gerds TA, Lip GY, et al.. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med. 2018, 283:45-55. 10.1111\/joim.12683","journal-title":"J Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-017-1009-9","article-title":"Real-life use of rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry","volume":"25","author":"Pisters R","year":"2017","unstructured":"Pisters R, van Vugt SP, Brouwer MA, et al.. Real-life use of rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J. 2017, 25:551-8. 10.1007\/s12471-017-1009-9","journal-title":"Neth Heart J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.028669","article-title":"Potential embolic sources and outcomes in embolic stroke of undetermined source in the NAVIGATE-ESUS trial","volume":"51","author":"Ntaios G","year":"2020","unstructured":"Ntaios G, Pearce LA, Veltkamp R, et al.. Potential embolic sources and outcomes in embolic stroke of undetermined source in the NAVIGATE-ESUS trial. Stroke. 2020, 51:1797-804. 10.1161\/STROKEAHA.119.028669","journal-title":"Stroke"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy224","article-title":"Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy","volume":"21","author":"Nagao T","year":"2019","unstructured":"Nagao T, Suzuki H, Matsunaga S, et al.. Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace. 2019, 21:590-7. 10.1093\/europace\/euy224","journal-title":"Europace"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.10.001","article-title":"A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial","volume":"231","author":"Guimar\u00e3es HP","year":"2021","unstructured":"Guimar\u00e3es HP, de Barros E Silva PG, Liporace IL, et al.. A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. Am Heart J. 2021, 231:128-36. 10.1016\/j.ahj.2020.10.001","journal-title":"Am Heart J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.03.018","article-title":"The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation","volume":"225","author":"Karthikeyan G","year":"2020","unstructured":"Karthikeyan G, Connolly SJ, Ntsekhe M, et al.. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. Am Heart J. 2020, 225:69-77. 10.1016\/j.ahj.2020.03.018","journal-title":"Am Heart J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.10.002","article-title":"A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens","volume":"134","author":"Provid\u00eancia R","year":"2014","unstructured":"Provid\u00eancia R, Grove EL, Husted S, Barra S, Boveda S, Morais J. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res. 2014, 134:1253-64. 10.1016\/j.thromres.2014.10.002","journal-title":"Thromb Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-020-0157-z","article-title":"Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study","volume":"6","author":"Miyazaki M","year":"2020","unstructured":"Miyazaki M, Matsuo K, Uchiyama M, et al.. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. J Pharm Health Care Sci. 2020, 6:2. 10.1186\/s40780-020-0157-z","journal-title":"J Pharm Health Care Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/0733464820978612","article-title":"Prevalent insomnia concerns and perceived need for sleep intervention among direct-care workers in long-term care","volume":"41","author":"Lee S","year":"2022","unstructured":"Lee S, Vigoureux TF, Hyer K, Small BJ. Prevalent insomnia concerns and perceived need for sleep intervention among direct-care workers in long-term care. J Appl Gerontol. 2022, 41:274-84. 10.1177\/0733464820978612","journal-title":"J Appl Gerontol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.09.063","article-title":"Impact of diabetes mellitus on short term vascular complications after TAVR: results from the BRAVO-3 randomized trial","volume":"297","author":"Goel R","year":"2019","unstructured":"Goel R, Power D, Tchetche D, et al.. Impact of diabetes mellitus on short term vascular complications after TAVR: results from the BRAVO-3 randomized trial. Int J Cardiol. 2019, 297:22-9. 10.1016\/j.ijcard.2019.09.063","journal-title":"Int J Cardiol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes","volume":"63","author":"Hylek EM","year":"2014","unstructured":"Hylek EM, Held C, Alexander JH, et al.. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014, 63:2141-7. 10.1016\/j.jacc.2014.02.549","journal-title":"J Am Coll Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.12.023","article-title":"Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation","volume":"132","author":"Graham DJ","year":"2019","unstructured":"Graham DJ, Baro E, Zhang R, et al.. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019, 132:596-604.e11. 10.1016\/j.amjmed.2018.12.023","journal-title":"Am J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study","volume":"172","author":"Fralick M","year":"2020","unstructured":"Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med. 2020, 172:463-73. 10.7326\/M19-2522","journal-title":"Ann Intern Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation","volume":"176","author":"Graham DJ","year":"2016","unstructured":"Graham DJ, Reichman ME, Wernecke M, et al.. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016, 176:1662-71. 10.1001\/jamainternmed.2016.5954","journal-title":"JAMA Intern Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-016-0189-9","article-title":"Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare Part D Data","volume":"17","author":"Hernandez I","year":"2017","unstructured":"Hernandez I, Zhang Y. Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs. 2017, 17:37-47. 10.1007\/s40256-016-0189-9","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation","volume":"150","author":"Noseworthy PA","year":"2016","unstructured":"Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016, 150:1302-12. 10.1016\/j.chest.2016.07.013","journal-title":"Chest"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.016275","article-title":"Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis","volume":"48","author":"Bai Y","year":"2017","unstructured":"Bai Y, Deng H, Shantsila A, Lip GY. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke. 2017, 48:970-6. 10.1161\/STROKEAHA.116.016275","journal-title":"Stroke"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs R","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, Brenner B, et al.. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010, 363:2499-510. 10.1056\/NEJMoa1007903","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99818-4","article-title":"Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation","volume":"11","author":"Gozzo L","year":"2021","unstructured":"Gozzo L, Di Lenarda A, Mammarella F, et al.. Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation. Sci Rep. 2021, 11:20689. 10.1038\/s41598-021-99818-4","journal-title":"Sci Rep"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-018-0501-7","article-title":"Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data","volume":"31","author":"Di Lullo L","year":"2018","unstructured":"Di Lullo L, Tripepi G, Ronco C, et al.. Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data. J Nephrol. 2018, 31:751-6. 10.1007\/s40620-018-0501-7","journal-title":"J Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/222007-assessing-the-safety-and-efficacy-of-rivaroxaban-for-stroke-prevention-in-patients-with-atrial-fibrillation-a-systemic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T19:32:19Z","timestamp":1708025539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/222007-assessing-the-safety-and-efficacy-of-rivaroxaban-for-stroke-prevention-in-patients-with-atrial-fibrillation-a-systemic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.54252","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}